OncoTrack
Methods for systematic next generation oncology biomarker development
groups: IMI Projects
tags: IMI Translational Medicine
- First Name
- David
- Last Name
- Henderson
- Affiliation
- Bayer AG
- david.henderson@bayer.com
- Business Phone Number
- 00493040008769
- Business Fax Number
- -
- Business Address
- Bayer AG, R&D Policy & Networking, 13342 Berlin, Germany
- Project Website
- http://www.oncotrack.eu
- Version
- V1.0
- Date of creation of the dataset
- 2017-01-05
- Date of the last update of the dataset
- 2017-01-05
- Funding
- IMI
- Data Standards Implemented
- CDISC
- Therapeutic Area Standards (Disease Area)
- -
- Study Protocal Description
- OncoTrack attempts to address the core problems of drug-based cancer therapies: the low response rate of patients to their therapies, as well as its inevitable consequence, the low approval rates of oncology drugs. Only about 10% of cancer drug candidates entering clinical development are granted marketing authorization. Our program is based on two seminal developments: significant progress in our ability to analyze the molecular characteristics of individual tumors and patients (predominantly, but not exclusively, due to advancements in DNA sequencing techniques) and through the development of sophisticated computational models, which can convert this abundance of data into predictions. To address this challenge, the OncoTrack consortium recruited over 300 colon cancer patients (stages I-IV) and developed a pre-clinical platform generating a compendium of drug sensitivity data totalling > 4,000 assays testing 16 clinical drugs on patient-derived in vivo and in vitro models. This large biobank of tumors, organoid culturess and xenografts, with extensive omics data comparing donor tumors and derived models, provides a resource for advancing our understanding of colon cancer.
- Multi-center Study
- True
- Description of Cohorts
- (1) Patients with primary diagnosis of colon cancer (2) Patients with metastatic colon cancer (3) Validation cohort of patients receiving therapy with 5FU
- Study Type
- Observational; Xenografts; 3D cell cultures
- Study Type Comment
- -
- Primary Purpose
- Biomarker discovery and validation
- Study Phase
- N/A - not a clinical trial
- Intervention Model
- N/A
- Study Classification
- N/A
- Indication
- Carcinoma of the colon
- Age Range (Low Limit) of Study
- 18
- Age Range (Upper Limit) of Study
- 93
- Age Unit (of the above ranges)
- Year
- BMI Range
- N/A
- BMI Range (lower limit)
- -
- BMI Range (upper limit)
- -
- Informed Consent
- True
- Planned Arm (Description of Sub-cohorts)
- -
- Name of Treatment
- Drugs tested: Oxaliplatin, Irinotecan, 5-FU, Cetuximab, AZD8931, AZD6244, Afatinib, Avastin, Regorafenib, Nintedanib, mTOR FR, BI836842 (IGF1/2 mAb), AZ1 (Tank-I), Volitinib
- Standardized Name of Treatment
- N/A
- Category
- Antineoplastics
- Dose Description
- Various
- Organism
- Homo sapiens
- Body System or Organ Class
- Colon cancer
- Total Number of (Human) Subjects
- 322
- Total Number of (Non-Human) Subjects
- 322
- Number of Subjects in Each Cohorts (if multi-cohorts)
- (1) 261 primary tumor (2) 61 metastatic tumor
- Detail Subject Composition
- No control cohort
- Type of Samples Collected
- Blood Serum Plasma Tumor Tissue Healthy Surrounding Tissue (near tumor)
- Number of Samples Collected
- >6000
- Samples Details
- -
- Secondary Analysis
- Whole genome sequencing, Exome sequencing, Transcriptome array, Methylation array, MicroRNA array, RNASeq, Proteomics, Deep-Sequencing
- FAIR indicators
- RDA indicator v0.03
- FAIR score, overall
- 35.0%
- FAIR score, mandatory indicators
- 46.0%
- FAIR score, recommended indicators
- 13.0%
- FAIR assessment details
- Post-FAIRification assessment
- Dataset link
- OncoTrack public sample metadata, FAIRifed v1